Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis

Mark C. Genovese, Joan M. Bathon, Roy M. Fleischmann, Larry W. Moreland, Richard W. Martin, James B. Whitmore, Wayne H. Tsuji, Jonathan A. Leff

Research output: Contribution to journalArticle

Abstract

Objective. To evaluate safety, efficacy, and radiographic progression in patients with early rheumatoid arthritis (RA) undergoing longterm treatment with etanercept. Methods. Patients with early RA (disease duration of 3 years or less) who had completed a 2-year efficacy study comparing etanercept and methotrexate (MTX) were followed in an extension where they received 25 mg etanercept twice weekly. Safety was summarized descriptively and compared with data from the efficacy study. Efficacy and radiographic progression were assessed using American College of Rheumatology response criteria, disease activity scores, and Total Sharp Score (TSS). Results. Rates of serious adverse events and serious infections did not increase with longterm exposure to etanercept, and were similar to rates reported for the blinded portion of the efficacy study. Efficacy was sustained in patients who completed 5 years of etanercept treatment at the time of this report (N = 201), even in those who decreased or discontinued use of MTX or corticosteroids. No radiographic progression (change in TSS ≤ 0) was seen in 55% of patients with 5-year radiographs; negative change (TSS <0) was seen in 11%. Conclusion. Etanercept treatment in patients with early RA was generally well tolerated for up to 5 years. The results indicate sustained efficacy and decreased rate of radiographic progression. The rate of radiographic progression was low compared with other studies, emphasizing the benefit gained in patients with early aggressive RA who undergo longterm treatment with etanercept.

Original languageEnglish (US)
Pages (from-to)1232-1242
Number of pages11
JournalJournal of Rheumatology
Volume32
Issue number7
StatePublished - Jul 2005

Fingerprint

Rheumatoid Arthritis
Safety
Methotrexate
Therapeutics
Etanercept
Adrenal Cortex Hormones
Infection

Keywords

  • Biological response modifiers
  • Clinical trials
  • Etanercept
  • Rheumatoid arthritis
  • Treatment

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Genovese, M. C., Bathon, J. M., Fleischmann, R. M., Moreland, L. W., Martin, R. W., Whitmore, J. B., ... Leff, J. A. (2005). Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. Journal of Rheumatology, 32(7), 1232-1242.

Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. / Genovese, Mark C.; Bathon, Joan M.; Fleischmann, Roy M.; Moreland, Larry W.; Martin, Richard W.; Whitmore, James B.; Tsuji, Wayne H.; Leff, Jonathan A.

In: Journal of Rheumatology, Vol. 32, No. 7, 07.2005, p. 1232-1242.

Research output: Contribution to journalArticle

Genovese, MC, Bathon, JM, Fleischmann, RM, Moreland, LW, Martin, RW, Whitmore, JB, Tsuji, WH & Leff, JA 2005, 'Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis', Journal of Rheumatology, vol. 32, no. 7, pp. 1232-1242.
Genovese MC, Bathon JM, Fleischmann RM, Moreland LW, Martin RW, Whitmore JB et al. Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. Journal of Rheumatology. 2005 Jul;32(7):1232-1242.
Genovese, Mark C. ; Bathon, Joan M. ; Fleischmann, Roy M. ; Moreland, Larry W. ; Martin, Richard W. ; Whitmore, James B. ; Tsuji, Wayne H. ; Leff, Jonathan A. / Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. In: Journal of Rheumatology. 2005 ; Vol. 32, No. 7. pp. 1232-1242.
@article{89b18f3d5e6d420a8dd0dbe765a59733,
title = "Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis",
abstract = "Objective. To evaluate safety, efficacy, and radiographic progression in patients with early rheumatoid arthritis (RA) undergoing longterm treatment with etanercept. Methods. Patients with early RA (disease duration of 3 years or less) who had completed a 2-year efficacy study comparing etanercept and methotrexate (MTX) were followed in an extension where they received 25 mg etanercept twice weekly. Safety was summarized descriptively and compared with data from the efficacy study. Efficacy and radiographic progression were assessed using American College of Rheumatology response criteria, disease activity scores, and Total Sharp Score (TSS). Results. Rates of serious adverse events and serious infections did not increase with longterm exposure to etanercept, and were similar to rates reported for the blinded portion of the efficacy study. Efficacy was sustained in patients who completed 5 years of etanercept treatment at the time of this report (N = 201), even in those who decreased or discontinued use of MTX or corticosteroids. No radiographic progression (change in TSS ≤ 0) was seen in 55{\%} of patients with 5-year radiographs; negative change (TSS <0) was seen in 11{\%}. Conclusion. Etanercept treatment in patients with early RA was generally well tolerated for up to 5 years. The results indicate sustained efficacy and decreased rate of radiographic progression. The rate of radiographic progression was low compared with other studies, emphasizing the benefit gained in patients with early aggressive RA who undergo longterm treatment with etanercept.",
keywords = "Biological response modifiers, Clinical trials, Etanercept, Rheumatoid arthritis, Treatment",
author = "Genovese, {Mark C.} and Bathon, {Joan M.} and Fleischmann, {Roy M.} and Moreland, {Larry W.} and Martin, {Richard W.} and Whitmore, {James B.} and Tsuji, {Wayne H.} and Leff, {Jonathan A.}",
year = "2005",
month = "7",
language = "English (US)",
volume = "32",
pages = "1232--1242",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "7",

}

TY - JOUR

T1 - Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis

AU - Genovese, Mark C.

AU - Bathon, Joan M.

AU - Fleischmann, Roy M.

AU - Moreland, Larry W.

AU - Martin, Richard W.

AU - Whitmore, James B.

AU - Tsuji, Wayne H.

AU - Leff, Jonathan A.

PY - 2005/7

Y1 - 2005/7

N2 - Objective. To evaluate safety, efficacy, and radiographic progression in patients with early rheumatoid arthritis (RA) undergoing longterm treatment with etanercept. Methods. Patients with early RA (disease duration of 3 years or less) who had completed a 2-year efficacy study comparing etanercept and methotrexate (MTX) were followed in an extension where they received 25 mg etanercept twice weekly. Safety was summarized descriptively and compared with data from the efficacy study. Efficacy and radiographic progression were assessed using American College of Rheumatology response criteria, disease activity scores, and Total Sharp Score (TSS). Results. Rates of serious adverse events and serious infections did not increase with longterm exposure to etanercept, and were similar to rates reported for the blinded portion of the efficacy study. Efficacy was sustained in patients who completed 5 years of etanercept treatment at the time of this report (N = 201), even in those who decreased or discontinued use of MTX or corticosteroids. No radiographic progression (change in TSS ≤ 0) was seen in 55% of patients with 5-year radiographs; negative change (TSS <0) was seen in 11%. Conclusion. Etanercept treatment in patients with early RA was generally well tolerated for up to 5 years. The results indicate sustained efficacy and decreased rate of radiographic progression. The rate of radiographic progression was low compared with other studies, emphasizing the benefit gained in patients with early aggressive RA who undergo longterm treatment with etanercept.

AB - Objective. To evaluate safety, efficacy, and radiographic progression in patients with early rheumatoid arthritis (RA) undergoing longterm treatment with etanercept. Methods. Patients with early RA (disease duration of 3 years or less) who had completed a 2-year efficacy study comparing etanercept and methotrexate (MTX) were followed in an extension where they received 25 mg etanercept twice weekly. Safety was summarized descriptively and compared with data from the efficacy study. Efficacy and radiographic progression were assessed using American College of Rheumatology response criteria, disease activity scores, and Total Sharp Score (TSS). Results. Rates of serious adverse events and serious infections did not increase with longterm exposure to etanercept, and were similar to rates reported for the blinded portion of the efficacy study. Efficacy was sustained in patients who completed 5 years of etanercept treatment at the time of this report (N = 201), even in those who decreased or discontinued use of MTX or corticosteroids. No radiographic progression (change in TSS ≤ 0) was seen in 55% of patients with 5-year radiographs; negative change (TSS <0) was seen in 11%. Conclusion. Etanercept treatment in patients with early RA was generally well tolerated for up to 5 years. The results indicate sustained efficacy and decreased rate of radiographic progression. The rate of radiographic progression was low compared with other studies, emphasizing the benefit gained in patients with early aggressive RA who undergo longterm treatment with etanercept.

KW - Biological response modifiers

KW - Clinical trials

KW - Etanercept

KW - Rheumatoid arthritis

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=22244476682&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22244476682&partnerID=8YFLogxK

M3 - Article

C2 - 15996057

AN - SCOPUS:22244476682

VL - 32

SP - 1232

EP - 1242

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 7

ER -